Search clinical trials for: Early-Stage NSCLC

Total 3623 results

Taizhou Hospital

Not yet recruiting

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Lung Cancer, Nonsmall Cell
Pfizer

Not yet recruiting

A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.

Lung Cancer
Immune Oncology Research Institute
Agenus Inc.

Recruiting

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Non-small Cell Lung Cancer

Armenia
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy (NeoIM-Lung)

NSCLC

China
Tianjin Medical University Cancer Institute and...

Recruiting

Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion.

NSCLC | Surgery | Radiotherapy

China
MedSIR
Medical University of Vienna

Not yet recruiting

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE)

NSCLC | Brain Metastases | ROS1 Gene Rearrangement
Jiangsu Province Nanjing Brain Hospital

Recruiting

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

NSCLC

China
Fudan University

Recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
Tubulis GmbH

Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (NAPISTAR1-01)

Ovarian Cancer | Non-small Cell Lung Cancer

United States
Suzhou Genhouse Bio Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)

United States
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (NEOVADE)

Non Small Cell Lung Cancer | EGFR Gene Mutation

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Dizal Pharmaceuticals

Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Non-small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Toripalimab Combined With SBRT for NSCLC

Non-small Lung Cancer

China
Zhejiang University

Not yet recruiting

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

EGF-R Positive Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Guangdong Association of Clinical Trials

Not yet recruiting

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung | Brain Metastases | Leptomeningeal Metastasis

China
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
Sun Yat-sen University

Recruiting

Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.

Non-small Cell Lung Cancer | Cardiac Toxicity

China
Tongji University
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Camrelizumab
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain, Turkey
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Thailand, Slovakia, Argentina, Taiwan, Brazil, Hong Kong
University of Rochester

Recruiting

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax (DRO2301)

Radiotherapy | Stage 4 NSCLC

United States
TYK Medicines, Inc

Recruiting

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

NSCLC

China
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Non-small Cell Lung Cancer

China
Brigham and Women's Hospital

Not yet recruiting

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

Pathologic Processes | Lung Cancer | Lymph Node Metastasis
Yonsei University

Not yet recruiting

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases (ELPIS)

Non Small Cell Lung Cancer

Korea, Republic of
Groupe Français de Pneumo-Cancérologie

Recruiting

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion (RESAMEX)

Non-small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

France
Ryan Gentzler, MD
Mirati Therapeutics Inc.; University of Virginia

Recruiting

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

NSCLC | Non Small Cell Lung Cancer | KRAS G12C

United States
Korea Institute of Oriental Medicine

Recruiting

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of
Eikon Therapeutics

Recruiting

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

NSCLC

United States
AstraZeneca

Recruiting

Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations

Non-small-cell Lung Cancer

Russian Federation
Xiangya Hospital of Central South University

Recruiting

Efficacy and Safety of NSCLC Patients With/Without Adjuvant Immunotherapy Who Have Achieved pCR After Neoadjuvant Immunotherapy

Resectable/Potentially Resectable NSCLC

China
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
JS InnoPharm, LLC

Recruiting

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Melanoma | NSCLC | Solid Tumor

China
AbbVie

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Small Cell Lung Cancer

United States, Israel, Japan
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) (GALILEO)

NSCLC Stage IV | ALK Gene Mutation | ALK Sensitizing Mutation

Italy
Nanfang Hospital, Southern Medical University

Recruiting

An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore

Non-small Cell Lung Cancer

China
University of California, Davis
United States Department of Defense

Recruiting

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Metastatic Nonsmall Cell Lung Cancer

United States
Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
University of Michigan Rogel Cancer Center

Recruiting

Gilteritinib for the Treatment of ALK NSCLC

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
University of California, Irvine

Recruiting

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

Non Small Cell Lung Cancer

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

NSCLC
Newsoara Biopharma Co., Ltd.

Not yet recruiting

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

NSCLC Stage IV
Radboud University Medical Center
Pfizer; ImaginAb, Inc.; University Hospital Tuebingen

Not yet recruiting

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor (IMPRINT)

NSCLC

Germany, Netherlands
European Organisation for Research and Treatment...

Not yet recruiting

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC (ICARS)

NSCLC Stage IV

3

Subscribe